BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 31816869)

  • 1. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes.
    Yu RTD; Garcia RL
    Sci Rep; 2020 Jul; 10(1):11028. PubMed ID: 32620824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.
    Kuhn N; Klinger B; Uhlitz F; Sieber A; Rivera M; Klotz-Noack K; Fichtner I; Hoffmann J; Blüthgen N; Falk C; Sers C; Schäfer R
    Adv Biol Regul; 2021 Jan; 79():100778. PubMed ID: 33431353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
    Awidi M; Ababneh N; Shomaf M; Al Fararjeh F; Owaidi L; AlKhatib M; Al Tarawneh B; Awidi A
    PLoS One; 2019; 14(12):e0226473. PubMed ID: 31881025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
    Costigan DC; Dong F
    Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
    Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
    J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validation of coexisting driver mutations in colorectal cancers.
    Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?
    Lin MT; Zheng G; Tseng LH; Zhang P; Ling H; Azad N; Gocke CD; Montgomery E; Eshleman JR
    Hum Pathol; 2020 Apr; 98():120-128. PubMed ID: 32171651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
    Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
    Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer.
    Ounissi D; Weslati M; Boughriba R; Hazgui M; Bouraoui S
    Turk J Med Sci; 2021 Feb; 51(1):148-158. PubMed ID: 32892548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.